Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.
Blood tests for tumor cells offer myeloma patients and doctors a gentler way to monitor disease without repeated bone marrow biopsies.
This review synthesizes current evidence on circulating tumor cells as a liquid biopsy approach in multiple myeloma, detailing their prognostic and monitoring utility across disease stages. The paper maps how CTCs bridge peripheral blood sampling with central bone marrow pathobiology in a disease traditionally requiring invasive bone marrow evaluation.
What the study was
- Study design
- Narrative review
- Population
- Multiple myeloma patients
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- American journal of hematology
Why it surfaced
Solid review from Am J Hematol on CTCs in multiple myeloma by high-profile myeloma investigators (Ghobrial, Paiva). Standard addition; no new data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.